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SUMMARY 
It is the Canadian public policy issue that rears its head with regularity, never 
achieving much more than discussion, and yet never going away entirely. The 
issue is pharmacare, and once again it is back for discussion among academics 
and policy-makers, and once again it looks like the discussions will not go 
anywhere anytime soon. The proposal for a publicly funded pharmaceutical-
coverage plan is frequently on the table in Canada, but it still is not in the cards.
Canada is the only member country of the Organisation for Economic Co-
operation and Development (OECD) with a public health-care system that does 
not include coverage for pharmaceuticals. As a result, Canada spends markedly 
less public money than the OECD average on pharmaceuticals (42 per cent of 
drug payments are public funds, versus the average 70 per cent), although it also 
spends more than the OECD average on hospitals and doctor visits. Advocates 
for an expansion of the publicly funded medicare system to include prescription 
medication note that it has become common for some lower-income Canadians 
who lack private drug insurance to leave prescriptions unfilled due to the cost, or 
will miss doses. This affordability problem for lower-income Canadians appears 
to be getting more serious.
However, while Canadians seem to express support for the idea of pharmacare 
when asked about it in surveys, it remains well behind a list of other improvements 
to the health-care system that they consider to be of higher priority. They are 
more interested in improving access and wait times, and they are more concerned 
about the sustainability of the current system given the increased demands of 
the aging population. Both employers and workers, meanwhile, also support the 
existing model of employer-provided drug plans. 
Perhaps the biggest obstacle for champions of pharmacare, however, is that the 
term can mean so many different things to different people. There is virtually no 
consensus on what would even be the appropriate Canadian system, particularly 
in light of how significant a factor private coverage already is in Canada. A pharmacare 
plan might include anything from the drastic step of eliminating all private coverage 
and subsidizing all prescription medicine for all patients regardless of income, to a much 
narrower program that covers some portion of the cost of only some drugs, for some 
income levels. There are also countless different possible models between those two. The 
matter of how much each level of government, provincial/territorial or federal, would be 
responsible for funding drugs is a whole other, rather thorny matter. 
The timing of this latest discussion about pharmacare — stimulated mainly by recent 
proposals and fuelled by the success of the pan-Canadian Pharmaceutical Alliance in 
negotiating better bulk drug prices — is also particularly unfavourable. There has been a 
sudden shift in the dynamic between the federal government and the provinces, where 
before premiers stood together and collectively bargained with the federal government 
for health-care funding, but recently splintered and are now making individual deals 
(while Quebec continues to insist that it must have complete freedom from Ottawa to 
design its own health system). The difficult fiscal situation across Canada, with so many 
governments running up debts, would also seem to make it highly unlikely that there 
will be much enthusiasm for embarking on a new and sizeable social program costing 
billions of dollars a year. Lacking enough leaders to passionately champion it, and with a 
public generally uninterested and very unclear on what a national pharmacare program 
would even entail, it seems that the current discussion about implementing a pharmacare 
system may come to a stall, like so many discussions before it.
1SUMMARY
Since the introduction of medicare in Canada in the 1950s and ’60s for hospital and medical 
care, the goal of universal coverage for prescription drugs has been an elusive one. In 
2014, of the estimated $29.4 billion spent in Canada on prescription drugs (accounting for 
13.6 per cent of total health spending), governments accounted for 42.6 per cent of that 
spending, and private insurers and out-of-pocket payment accounted for 35.2 and 22.2 per 
cent respectively.1 Lately, there has been a resurgence of interest in a national drug plan 
(following proposals by Gagnon in 2010 and Morgan and colleagues in 2015) fuelled by 
the success of the pan-Canadian Pharmaceutical Alliance (pCPA) in lowering prices of 
brand-name and generic prescription drugs for government-funded drug plans. Hence, the 
question is being raised again: Has the time come for national pharmacare? 
This note reviews the recent developments and discusses some of the key considerations in 
moving forward, including: the cost, the federal/provincial-territorial dynamics, the issue of 
winners and losers, and the level of support from the Canadian public and key stakeholders. 
Based on these considerations, the answer to the question is “not yet.” Hopefully, the report 
of the study on national pharmacare being conducted by the House of Commons standing 
committee on health, expected some time in 2017, will result in serious deliberation and 
progress toward universal access to prescription drugs in Canada.
THE UNFINISHED BUSINESS OF MEDICARE
Pharmacare is clearly part of the unfinished business of medicare. Numerous authors have 
pointed out that Canada is the only developed country that does not include prescription 
drugs as part of its universal health program. Table 1 below shows how Canada compares 
on the proportion of public spending for major categories of health expenditure with the 
22 member countries of the Organisation for Economic Co-operation and Development 
(OECD) for which data were available for 2012.
TABLE 1  PUBLIC SPENDING AS PER CENT OF TOTAL SPENDING: MAJOR HEALTH SPENDING CATEGORIES, 
CANADA AND 22-OECD-COUNTRY AVERAGE, 2012
% Public Spending
Prescription Drugs Hospitals Doctors’ Offices Dentists’ Offices
Canada 42 91 99 6
OECD Average 70 88 72 34
Source: OECD.Stat, Doctors’ offices figure for Sweden is 2009.
In the case of prescription medications, Canada was more than one-third (40-per-cent) 
below the OECD average.
As a result of prescription drugs not being included in medicare, there is wide variation 
today in provincial-territorial (PT) government per-capita spending on prescription drugs. 
Table 2 shows that, for 2014, PT government per-capita expenditure on prescription drugs 
ranged across the provinces from $196 in British Columbia and $219 in Prince Edward 
Island, to $317 in Alberta and $348 in Ontario, according to estimates from the Canadian 
1 “Prescribed Drug Spending in Canada, 2016: A Focus on Public Drug Programs” (Canadian Institute for Health Information, 
2016), https://secure.cihi.ca/free_products/Prescribed%20Drug%20Spending%20in%20Canada_2016_EN_web.pdf.
2Institute for Health Information (CIHI).2 CIHI does not provide estimates of private per-
capita prescription drug spending (private insurance plus out-of-pocket payments) below 
the national level.
TABLE 2 SPENDING ON PRESCRIPTION DRUGS: SELECTED INDICATORS BY PROVINCE AND TERRITORY
Province/ Territory PT govt. spending
a 2014
($million)
PT govt. spending  
per capita,a 2014
($million )
Private insurance,b 2014
($million)
Average household  
out-of-pocket,c $2015
NL  142.6  269 177  440
PE  32.0  219 32  456
NS  266.9  283 337  401
NB  179.9  238 284  444
QC  2,480.8  302 2,369  526
ON  4,753.5  348 4,626  314
MB  303.8  237 249  459
SK  322.1  287 192  491
AB  1,308.1  317 1,065  373
BC  908.1  196 894  498
YT  7.9  214 -  -
NT  7.7  174 -  -
NU  4.9  136 -  -
Territories  20.5  175 23  -
Canada 10,718.3  302 10,247  417
a CIHI, National Health Expenditure Database 1975-2016, Table C.4.1, C.4.3,D.4.1-13.
b Canadian Life and Health Insurance Association.
c Statistics Canada, Survey of Household Spending, 2015.
Table 2 also shows the significant role of private insurance in every region of Canada. 
Data provided by the Canadian Life and Health Insurance Association, shown in Column 
3 of Table 2, show that private health insurance companies paid out $10.2 billion for 
prescription drug claims in 2014, representing 96 per cent of the $10.7 billion paid for by 
PT governments. In three provinces — Newfoundland and Labrador, Nova Scotia and New 
Brunswick — the amount paid by private insurance exceeds that paid by governments. 
Table 2 also shows that there is wide variation in average household out-of-pocket spending 
on prescription drugs, according to Statistics Canada’s Survey of Household Spending 
(SHS). In 2015, this ranged from a low of $314 in Ontario to a high of $498 in B.C.3 
Significant variation is evident when looking at household out-of-pocket spending on 
prescription drugs by income quintile (detailed data not shown). The pattern in most 
provinces is that the lowest income quintile has the lowest out-of-pocket spending and the 
second-lowest quintile has the highest. In Quebec for example, the second-lowest quintile 
spent $285 more on average than the lowest quintile ($665 versus $380).3 This pattern likely 
reflects the availability of public drug programs for those with the lowest incomes and 
2 
Canadian Institute for Health Information website, “National Health Expenditure Database 1975 to 2016,” Table D 4.1.1-
D4.13.1, https://www.cihi.ca/en/spending-and-health-workforce/spending/national-health-expenditure-trends, accessed 
February 24, 2017.
3 
Statistics Canada, CANSIM Table 203-0022, “Survey of household spending (SHS), household spending, Canada, regions 
and provinces, by household income quintile.”
3who lack private coverage. This is supported by a Wellesley Institute analysis of Statistics 
Canada’s 2011 Survey of Labour and Income Dynamics that showed that fewer than one in 
three people earning less than $20,001 annually had employer-provided medical benefits 
compared with three out of four (or greater) in income groups earning more than $30,000.4 
It is also evident that out-of-pocket prescription drug costs are a particular issue for seniors. 
Average out-of-pocket spending for households headed by someone 65 years old or older in 
2015 ($646) was 55-per-cent greater than the average for all households ($417).5 Moreover, 
in a detailed analysis of the 2009 Survey of Household Spending, Caldbick et al. found that 
households headed by a senior were three times as likely as the household average to report 
spending three per cent of their household income on prescription drugs (22.5 versus 8.2 
per cent).6 
Aside from overall differences in public spending, there are also differences across 
provinces and territories in which medications are covered, particularly in the case of 
cancer drugs. The Cancer Advocacy Coalition of Canada reported in 2014 that four 
provinces fully fund access to cancer medications taken outside a hospital. In Ontario and 
Atlantic Canada, however, full provincial funding is limited to cancer drugs that must be 
taken in a hospital setting and are on the provincial formulary; if the drug is taken outside 
of hospital (oral or injectable), the patient and family may have to pay significant out-of-
pocket costs.7 More generally, the Canadian Cancer Society has reported that persons 
moving from one province to another may find that a medication covered in their former 
province is not covered in the new one.8 A recent qualitative key informant study also 
reported significant differences in public coverage of prescription drugs for neurological 
conditions across jurisdictions.9
Other sources confirm that the cost of prescription medication is an issue for many 
Canadians. In the Commonwealth Fund’s 2013 International Health Policy Survey of adults 
age 18 and over, eight per cent of the Canadian respondents said that they had either not 
filled a prescription or skipped doses because of cost issues.10 On its 2014 survey of older 
adults 55 and over, seven per cent of Canadian respondents reported having done so.11 
On the 2016 survey of adults age 18 and over, the percentage of Canadian respondents 
with a cost barrier to prescription drugs had increased to 10 per cent, and those with 
4 
Steve Barnes and Laura Anderson, “Low earnings, Unfilled Prescriptions: Employer-Provided Health Benefit Coverage 
in Canada” (Wellesley Institute, 2015), http://www.wellesleyinstitute.com/wp-content/uploads/2015/07/Low-Earnings-
Unfilled-Prescriptions-2015.pdf.
5 
Statistics Canada, CANSIM Table 203-0026, “Survey of household spending (SHS), household spending, by age of 
reference person.”
6 
S. Caldbick et al., “The financial burden of out of pocket prescription drug expenses in Canada,” International Journal of 
Health Economics and Management 15, 3 (2015): 329-38.
7 “2014-2015 Report Card on Cancer in Canada” (Cancer Advocacy Coalition of Canada, 2015), http://www.canceradvocacy.
ca/reportcard/2014/Report%20Card%20on%20Cancer%20in%20Canada%202014-2015.pdf.
8 “Cancer Drug Access for Canadians” (Canadian Cancer Society, 2009), http://www.colorectal-cancer.ca/IMG/pdf/cancer_
drug_access_report_en.pdf. 
9 
S. Guilcher et al., “The financial burden of prescription drugs for neurological conditions in Canada: results from the 
National Population Health Study of Neurological Conditions,” Health Policy (2017).
10 C. Schoen et al., “Access, affordability, and insurance complexity are often worse in the United States compared to ten other 
countries,” Health Affairs 32, 12 (2013): 2205-15.
11 “How Canada compares: results from the Commonwealth Fund 2014 international health policy survey of older adults” 
(Canadian Institute for Health Information 2014), https://www.cihi.ca/sites/default/files/document/common_survey_ppt_en.pptx.
4below-average incomes were more than four times as likely to report a cost barrier than 
those with above-average incomes (17 versus four per cent).12 In addition to the results 
of the Commonwealth Fund surveys, a 2015 survey by the Angus Reid Institute also 
asked Canadians about not renewing a prescription or splitting pills due to cost, finding 
that almost one in four respondents (23 per cent) reported that they or someone in their 
household had done one or both of those things.13 Himmelstein et al. reported on a survey 
of Canadians who experienced bankruptcy between 2008 and 2010. They found that 74.5 
per cent of the respondents who had had a medical bill within the last two years reported 
that prescription drugs were their biggest medical expense.14
At least two Canadian studies have documented the impact that out-of-pocket costs, lack 
of insurance and low income have on non-adherence15 to prescription regimens. Law et al. 
examined cost-related non-adherence in the 2007 Canadian Community Health Survey 
and found that those without drug insurance were more than four times as likely to report 
non-adherence than those with insurance. The predicted rate of non-adherence among those 
with low household incomes and no drug insurance was almost 10 times as high as that 
among those with high incomes and drug insurance (35.6 versus 3.6 per cent).16 Based on 
a large-scale study of the incidence of primary non-adherence (defined as not filling a new 
prescription within nine months) in a group of some 70,000 Quebec patients, Tamblyn et al. 
reported that there was a 63-per-cent reduction in the odds of non-adherence among those 
with free medication over those with the maximum level of co-payment. They also reported 
that the odds of non-adherence increased with the cost of the medication prescribed.17
In summary, there is no dispute than affordability of prescription drugs is an issue for many 
Canadians and it appears to be a growing one.
EVOLUTION OF PHARMACARE PROPOSALS
Since 1964 a number of proposals for pharmacare have been put forward. Appendix A 
provides a snapshot chronology that focuses on their implications for public funding. 
References are given in the paper.
1964-1997
In 1964, the Hall commission recommended 50/50 cost-sharing between the federal and 
provincial governments toward the establishment of a prescription drug program, with a 
$1.00 charge for each prescription. At the time, prescription drugs represented 6.5 per cent 
12 “How Canada compares: results from the Commonwealth Fund’s 2016 International Health Policy Survey of Adults 
in 11 Countries” (Canadian Institute for Health Information 2016), https://www.cihi.ca/sites/default/files/document/
commonwealth-fund-2016-chartbook-en-web-rev.pptx.
13 “Prescription drug access and affordability an issue for nearly a quarter of all Canadian households” (Angus Reid Institute, 
2015), http://angusreid.org/wp-content/uploads/2015/07/2015.07.09-Pharma.pdf. 
14 D. Himmelstein et al., “Health issues and health care expenses in Canadian bankruptices and insolvencies,” International 
Journal of Health Services 44, 1 (2014): 7-23.
15 
Non-adherence can be defined as doing something to make a medication last longer or failing to fill or renew a prescription. 
16 M. Law et al., “The effect of cost on adherence to prescription medications in Canada,” Canadian Medical Association 
Journal 184, 3 (2012.): 297-302.
17 R. Tamblyn et al., “The incidence and determinants of primary nonadherence with prescribed medication in primary care,” 
Annals of Internal Medicine 160 (2014): 441-50.
5of spending on personal health services.18 This recommendation was not implemented. 
Indeed, the federal and provincial health ministers appointed a committee on the costs of 
health services in February 1969, just seven months after medicare came into effect, and 
only two provinces had enrolled.19 In its November 1969 report, the committee highlighted 
that the cost of health services had more than doubled between 1957 and 1967 to reach $3.7 
billion and might reach $6.2 billion by 1972.19 The Hall report also contained 25 forward-
looking recommendations on pharmaceuticals that remain current to this day, including 
bulk purchasing, generic substitution and a national formulary.18
Subsequently, a proposal for a drug-price program was developed in 1971–72, which Boothe 
has documented in her recent monograph on the development of national pharmaceutical 
insurance in Australia and the United Kingdom, and the lack of it in Canada.20
The next concerted discussion on a national program for prescription drugs (pharmacare) 
did not occur until the National Forum on Health (NFH), which was struck in 1994 and 
reported in 1997. A working-group paper on pharmaceutical policy recommended first-dollar 
coverage for prescription drugs, but acknowledged that, if that could not occur overnight, 
“over time we propose to shift private funding on prescribed pharmaceuticals (estimated 
at $3.6 billion in 1994) to public funding.”21 The NFH included this recommendation in its 
final report, noting that “the absorption of currently operating plans by a public system may 
involve transfer of funding sources as well as administrative apparatus.”22 Such a significant 
shift is not without precedent. A study prepared for the Hall commission estimated that 
9.6-million Canadians, representing 53 per cent of the total population, had some form of 
not-for-profit or commercial insurance coverage for medical and/or surgical services in 
1961.23 These plans were all displaced as the provinces joined medicare.
It is instructive to place the 1994 prescription drug expenditure cited by the NFH in today’s 
context. According to the Bank of Canada’s inflation calculator, $6.5 billion in costs in 1994 
would be $9.29 billion in costs in 2014.24 The Canadian Institute for Health Information 
(CIHI) estimates that actual spending in 2014 was $29.4 billion25 — 216-per-cent above the 
level of 1994 spending (in 2014 dollars), compared to population growth of 23 per cent over 
the same time period.26 Annual prescription drug spending increases averaged 7.7 per cent 
over the period, although they have averaged just 1.6 per cent since 2010.27
18 Royal Commission on Health Services Report, Volume One (Ottawa: Queen’s Printer, 1964).
19 J. Munro, “Task force reports on the cost of health services in Canada. Volume 1 Summary” (Ottawa: Queen’s Printer for 
Canada, 1970).
20 K. Boothe, Ideas and the Pace of Change: National Pharmaceutical Insurance in Canada, Australia and the United 
Kingdom (Toronto: University of Toronto Press, 2015).
21 
“Directions for a Pharmaceutical Policy in Canada” (National Forum on Health), http://www.hc-sc.gc.ca/hcs-sss/pubs/
renewal-renouv/1997-nfoh-fnss-v2/index-eng.php.
22 
“Canada Health Action: Building on the Legacy” (National Forum on Health, 1997).
23 C. Berry, Voluntary Medical Insurance and Prepayment (Ottawa: Queen’s Printer, 1965).
24 
Bank of Canada website, Inflation calculator, http://www.bankofcanada.ca/rates/related/inflation-calculator/?page_moved=1.
25 CIHI, “Prescribed drug.”
26 Statistics Canada, Table 051-0001, “Estimates of population, by age group and sex for July 1, Canada, provinces and 
territories.”
27 
CIHI website, “National,” Table A.3.3.1, https://www.cihi.ca/en/spending-and-health-workforce/spending/national-health-
expenditure-trends. 
6A costing study for a pharmacare plan was put forward by Palmer D'Angelo Consulting 
Inc. in September 1997. They estimated that a fully public pharmacare plan would require 
increased public funding of $4.3 billion.28
1997-2012
Following the NFH report, in the 1997 speech from the throne, the government committed 
to “develop a national plan, timetable and a fiscal framework for providing Canadians with 
better access to medically necessary drugs,” but nothing further was made public.29 Of note, 
Quebec launched its universal drug plan in 1997, which included a mandate for all residents 
to have either private or public coverage.
In 1999, all first ministers except Quebec’s then premier, Lucien Bouchard, signed the 
Social Union Framework Agreement (SUFA). While it would seem that SUFA has been 
relegated to history, it is significant for having established principles to guide any future 
federal cost-shared program offerings in the health arena. SUFA included requirements 
for consultation and effectively provided for compensation for provinces and territories 
providing existing programs in areas where the federal government might wish to engage.30
In January 2000, then federal health minister Allan Rock wrote to his provincial 
counterparts to propose that they meet in May to discuss primary care, home and 
community care and accountability to Canadians through information about health 
outcomes.31 That provoked an immediate, hostile reaction from the provincial health 
ministers.32 This was noteworthy for two reasons. First there was no mention of 
pharmacare; second, this was a prelude to the first of three First Ministers’ Health Accords 
in September 2000.
Pharmacare was subsequently examined in two national studies, both of which recommended 
federal involvement in reimbursing “catastrophic” prescription drug expenditures that 
exceeded certain thresholds relative to household income. The Senate study on the state of 
the health-care system in Canada, chaired by Michael Kirby, was authorized in March 2001 
and the Commission on the Future of Health Care in Canada, headed by Roy Romanow, was 
approved in April 2001. Both issued their final reports in 2002.
The Kirby plan was designed so as to avoid the necessity of eliminating existing private 
plans or the provincial/territorial public plans, not unlike the approach taken by Quebec in 
1997. In the Kirby plan, in the case of public plans, personal prescription drug expenses 
for any family would be capped at three per cent of total family income. The federal 
government would then pay 90 per cent of prescription drug expenses in excess of $5,000. 
In the case of private plans, sponsors would have to agree to limit out-of-pocket costs 
28 
Palmer D'Angelo Consulting Inc. National pharmacare cost impact study. Ottawa, 1997. www.pdci.ca/publications/
Pharmacare%20Impact%20Study%20Final%20Report.pdf.
29 
Speech from the throne to open the first session 36th Parliament of Canada, http://www.pco-bcp.gc.ca/index.
asp?lang=eng&page=information&sub=publications&doc=aarchives/sft-ddt/1997-eng.htm.
30 “A Framework to Improve the Social Union For Canadians” (Canadian Intergovernmental Conference Secretariat, 1999), 
http://www.scics.ca/en/product-produit/agreement-a-framework-to-improve-the-social-union-for-canadians/.
31 A. Rock, Unpublished letter to provincial-territorial health ministers (January 2000).
32 A. Milroy, “Scorn greets Rock’s health plan,” The Globe and Mail, January 28, 2000, A1.
7to $1,500 per year, or three per cent of family incomes, whichever was less. The federal 
government would then agree to pay 90 per cent of drug costs in excess of $5,000 per year. 
Both public and private plans would be responsible for the difference between out-of-pocket 
costs and $5,000, and private plans would be encouraged to pool their risk. Kirby estimated 
that this plan would cost approximately $500 million per year.33
The Romanow commission recommended a $1-billion catastrophic drug transfer, through 
which the federal government would reimburse 50 per cent of the costs of provincial and 
territorial drug insurance plans above a threshold of $1,500 per person per year.34
Also in 2002 Palmer D'Angelo updated their 1997 study. Their estimate35 of the increased 
public funding for a fully public program had increased to $8.1 billion. Following the 
Kirby and Romanow reports, there was a back-and-forth exchange between the federal and 
provincial-territorial governments on a plan for catastrophic coverage. In their February 
2003 accord, first ministers agreed to ensure that Canadians would have reasonable access 
to catastrophic drug coverage by March 2006.36 Pharmacare was a campaign issue in 
the federal election held in June 2004. The federal Liberals pledged to work with the PT 
governments to “develop and help fund” a national pharmaceutical plan.37 The Conservative 
party committed to implementing the 2003 accord, including a proposal “that the federal 
government assume direct responsibility for the catastrophic plan in the Accord.”38 At their 
annual summer meeting a month later, the premiers called on the federal government to 
“assume full financial responsibility for a comprehensive drug program for all Canadians,” 
with compensation to Quebec for its existing drug program.39 In the September 2004 
health accord, first ministers directed health ministers to develop a nine-point “national 
pharmaceuticals strategy” (NPS), including costing options for catastrophic coverage.40 The 
2004 accord was also noteworthy for explicitly recognizing “asymmetrical federalism,” 
acknowledging a greater autonomy for Quebec than for other provinces. This document 
indicated that while Quebec supported the objectives and principles set out in the accord, 
it would develop its own plans for reducing wait times, managing health-care human 
resources, strategies for drug access, and other elements.41
A federal-provincial-territorial ministerial task force on the NPS was struck and a progress 
report was issued in June 2006. This report proposed four options for catastrophic 
33 The Health of Canadians – The Federal Role. Volume Six: Recommendations for Reform (Standing Senate Committee on 
Social Affairs, Science and Technology, 2002).
34 Building on Values: The Future of Health Care in Canada (Commission on the Future of Health Care in Canada, 2002).
35 Palmer D'Angelo Consulting Inc. Cost impact study for a national pharmacare program for Canada. September, 2002.  
www.pdci.ca/publications/National_Pharmacare_2002-Full_Report.pdf.
36 First Ministers’ Accord on Health Care Renewal (Canadian Intergovernmental Conference Secretariat, 2003),  
http://www.scics.gc.ca/CMFiles/800039004_e1GTC-352011-6102.pdf. 
37 
“Health care: a fix for a generation — costing the plan” (Liberal Party of Canada, 2004).
38 “Demanding better” (Conservative Party of Canada, 2004).
39 “Premiers’ action plan for better health care: resolving issues in the spirit of true federalism,” communiqué (Council of the 
Federation, July 30, 2004), http://canadaspremiers.ca/phocadownload/newsroom-2004/healtheng.pdf.
40 “A 10-year plan to strengthen health care” (Canadian Intergovernmental Conference Centre, ), http://www.scics.gc.ca/
CMFiles/800042005_e1JXB-342011-6611.pdf.
41 “Asymetrical federalism that respects Quebec’s jurisdiction” (Canadian Intergovernmental Conference Secretariat, 2004), 
http://www.scics.ca/wp-content/uploads/CMFiles/800042012_e1JWF-342011-9468.pdf.
8coverage, with estimates for new public funding ranging from $1.4 to $4.7 billion.42 Two 
stakeholder consultations were held with employers/insurers43 and health-professional 
associations44 in 2007, but nothing was heard publicly thereafter. At their September 2008 
meeting, the PT health ministers called for a national standard for drug coverage not to 
exceed five per cent of the provincial net income base, and for the federal government to 
share 50/50 in the estimated $5.03-billion cost.45 In its campaign platform for the October 
2008 election, the Liberal party pledged $900 million to work with the PT governments to 
establish a national minimum level of catastrophic coverage for which those jurisdictions 
meeting the level would be eligible for compensation.46 In January 2009, the Health Council 
of Canada described the situation of the NPS as being at an “impasse” and urged federal, 
provincial and territorial governments to come to the table to resolve the issues, noting that 
without such collaboration the NPS “will remain largely a prescription unfilled.”47
In the 2012 final parliamentary review of the 2004 health accord, the Senate committee 
on social affairs, science and technology heard concerns from witnesses about the lack of 
progress on a national standard for catastrophic coverage, and one of its recommendations 
(No. 28) called on the federal government to work with the PT governments to develop a 
“national pharmacare program based on the principles of universal and equitable access 
for all Canadians.”48 In its response, the federal government stated that the NPS work had 
stimulated individual provinces and territories to adopt catastrophic drug plans.49 In 2012, 
the federal government announced its intention to develop a framework to increase access 
to orphan drugs for rare diseases50 and in 2014 announced the launch of a pilot project for 
patient involvement to inform future reviews of orphan drugs.51
The Gagnon (2010) and Morgan (2015) Proposals
Since 2010, two proposals have sparked considerable interest in the prospect of a 
pharmacare program that would be offered on the same terms and conditions as medicare 
(principally single-public-payer coverage with either minimal or no co-payment). The 
42 
“National Pharmaceuticals Strategy progress report” (National Pharmaceuticals Strategy, 2006), http://www.hc-sc.gc.ca/
hcs-sss/alt_formats/hpb-dgps/pdf/pubs/2006-nps-snpp/2006-nps-snpp-eng.pdf.
43 
“Report to National Pharmaceuticals Strategy,” Catastrophic Drug Coverage Working Group: Insurers and employers 
stakeholder-engagement session, meeting summary (Victoria, B.C., September 17, 2007).
44 
“Report to National Pharmaceuticals Strategy,” Catastrophic Drug Coverage Working Group: Health-care professional 
associations stakeholder-engagement session, meeting summary (Victoria, B.C, October 2, 2007).
45 
“Backgrounder: National Pharmaceutical Strategy Decision Points” (Canadian Intergovernmental Conference Secretariat), 
http://www.scics.ca/en/product-produit/backgrounder-national-pharmaceutical-strategy-decision-points/. 
46 “Stéphane Dion announces new drug plan,” Liberal Party of Canada press release, September 16, 2008. 
47 
“A Commentary on the National Pharmaceutical Strategy: A Prescription Unfilled” (Health Council of Canada, 2009), 
http://www.healthcouncilcanada.ca/tree/2.35.1-HCC_NPS_Commentary_WEB.pdf. 
48 “Time for Transformative Change: A Review of the 2004 Health Accord” (Standing Senate Committee on Social Affairs, 
Science and Technology, 2012), http://www.parl.gc.ca/content/sen/committee/411/soci/rep/rep07mar12-e.pdf.
49 
Government of Canada, “Taking Action to Improve the Health of Canadians,” http://www.parl.gc.ca/Content/SEN/
Committee/411/soci/rep/rep07GovResponse-e.pdf. 
50 Health Canada, “Harper government takes action to help Canadians with rare diseases,” news release, October 3, 
2012, http://www.prnewswire.com/news-releases/harper-government-takes-action-to-help-canadians-with-rare-
diseases-172494101.html. 
51 Government of Canada, “Minister Ambrose announces patient involvement pilot for orphan drugs,” news release, August 6, 
2014, http://news.gc.ca/web/article-en.do?nid=873619.
9first was by Marc-André Gagnon in 2010, published for the Canadian Centre for Policy 
Alternatives. The proposal was developed on the basis of a review of cross-provincial 
and international practices in pharmaceutical policy. The review formed the basis of a set 
of 11 assumptions that were used to develop four scenarios that resulted in estimates of 
prescription drug cost savings over the 2008 baseline expenditure of $25.1 billion, ranging 
from $2.9 billion to $10.7 billion.52 The scenario with the greatest savings was based on 
adoption of New Zealand’s drug-purchasing policies53 and the results of the 11 parameters 
for this scenario are shown below.
 Source: Gagnon (2010).
In a 2014 update published by the Canadian Federation of Nurses Unions, Gagnon 
estimated that a first-dollar coverage program would save 10 to 41 per cent of prescription 
drug costs, representing savings of as much as $11.4 billion annually on a 2012–13 base of 
$27.7 billion.54 
Steve Morgan and colleagues have estimated that a universal public plan with small co-
payments could reduce prescription drug spending by $7.3 billion on a base of $22.3 total 
spending in 2012-13..55 The key modelling parameters for their base scenario and their 
associated savings are as follows:
• A change in generic prices of -$2.5 billion assumes that Canadian prices for generic 
drugs will fall to a level equal to moderately performing comparators, such as the 
U.K. and Sweden;
52 M. Gagnon, “The Economic Case for Universal Pharmacare” (Canadian Centre for Policy Alternatives, 2010),  
https://s3.amazonaws.com/policyalternatives.ca/sites/default/files/uploads/publications/National%20Office/2010/09/
Universal_Pharmacare.pdf. 
53 See: Pharmaceutical Management Agency, “Introduction to PHARMAC,” http://www.pharmac.govt.
nz/2011/09/16/01INTRO.pdf. 
54 
M. Gagnon, “A roadmap to a rational pharmacare policy in Canada” (Ottawa: Canadian Federation of Nurses Unions, 2014).
55 S. Morgan et al., “Estimated cost of universal public coverage of prescription drugs in Canada,” Canadian Medical 
Association Journal 187, 7 (2015): 491-497.
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• A change in brand-name prices of -$2.5 billion assumes Canadian prices fall to a level 
equal to the U.K., where patented drug prices are 23-per-cent lower than in Canada;
• A change in product selections within drug classes of -$2.7 billion assumes that off-
patent drugs are prescribed at the third-highest rate among provincial drug plans in 
Canada, and the same for generic prescribing rates;
• Increases in utilization of three per cent and $680 million in public spending; and
• Changes in co-payments assumes $2.00 for generics and $10.00 for brand-name drugs.56
The Morgan et al. paper has been accessed more than 28,000 times from March 2015 
through October 2016.57 In both the Gagnon and Morgan proposals, the majority of the 
savings are achieved through lower prices for generic and brand-name drugs. Both studies 
documented their modelling assumptions in detail and developed a range of estimates.
On June 3, 2015 the Liberal Senate Forum held an open caucus session on pharmacare58 and 
on June 8, 2015, Ontario Health Minister Eric Hoskins — in follow-up to his Dec. 15, 2014 
declaration that “the time for national pharmacare has come”59 — hosted his counterparts 
from seven other jurisdictions at a roundtable meeting that heard from Gagnon and Morgan 
and other academics and experts about the prospects for pan-Canadian pharmacare.60 The 
roundtable report identified eight areas of broad consensus, including acknowledgement of 
a gap in coverage and the potential for savings, as well as the need to improve the quality 
of prescribing. The report also identified five key issues to resolve, including first-dollar 
coverage, the reaction from the public and employers, and the question of whether federal 
government participation is necessary.61 
In July 2015, just prior to the annual meeting of premiers, Morgan and colleagues released 
Pharmacare 2020, which set out five recommendations calling for the establishment of 
pharmacare as a single-payer system with a publicly accountable management agency, 
to be fully implemented by 2020.62 The Pharmacare 2020 website presently lists almost 
300 endorsements. In the communiqué following their meeting, the premiers emphasized 
the importance of the pCPA and noted the prospect of the participation of the federal 
government, and also indicated that the PTs would examine pharmacare programs in other 
countries.63
In September 2015, there were three proposals for an approach to universal pharmacare 
that involved the continued participation of private plans. As part of its Pharmacare 2.0 
56 See S. Morgan et al., “Estimated,” Appendix 1: Technical details concerning cost modelling and Appendix 2: Sensitivity testing.
57 Canadian Medical Association Journal, unpublished tabulation.
58 Liberal Senate Forum, Open Caucus June 3, 2015 — Pharmacare, http://liberalsenateforum.ca/open-caucus/june-3-2015-pharmacare/. 
59 E. Hoskins, “The time for national pharmacare has come,”Toronto Star, December 15, 2014, https://www.thestar.com/
opinion/commentary/2014/12/15/eric_hoskins_the_time_for_national_pharmacare_has_come.html. 
60 Ontario Ministry of Health and Long-Term Care, joint statement by ministerial participants of pharmacare roundtable (June 8, 
2015), http://news.ontario.ca/mohltc/en/2015/06/joint-statement-by-ministerial-participants-of-pharmacare-roundtable.html. 
61 Health Quality Ontario, Ministers’ Roundtable on Pan-Canadian Pharmacare, http://www.health.gov.on.ca/en/common/
ministry/publications/reports/pancan_pharmacare/pancan_pharmacare.pdf.
62 S. Morgan et al., “Pharmacare 2020: The Future of Drug Coverage in Canada,” http://pharmacare2020.ca/assets/pdf/The_
Future_of_Drug_Coverage_in_Canada.pdf.
63 The Council of the Federation, “Health care remains a top priority,” news release, July 17, 2015,  
http://www.pmprovincesterritoires.ca/phocadownload/newsroom-2015/health_care-final.pdf. 
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initiative, the Canadian Pharmacists Association (CPhA) released a discussion paper that 
set out three principles and associated priorities toward achieving universal coverage. Under 
the principle “innovation and sustainability,” the CPhA proposed that a pan-Canadian 
pharmacare framework should be built on co-operation between public and private plans 
and should include means-tested patient contributions.64 As part of its 2015 federal election 
call for a national seniors strategy, the Canadian Medical Association released a report 
commissioned from the Conference Board of Canada that included a costing of the proposal 
put forward in the 2002 Kirby report. Using Statistics Canada’s Survey of Household 
Spending as the basis for its modelling, the Conference Board estimated that it would cost 
the federal government $1.6 billion in 2016 to cover prescription drug spending in excess 
of the lesser of amount of three per cent or $1,500 of annual household income.65 Blomqvist 
and Busby proposed something similar to Kirby: a “nationwide network of geared-to-
income (catastrophic) plans” whereby the federal government would transfer funds to 
provinces whose programs respect minimal conditions for an income-tested upper limit on 
household drug spending.66
The 2015 Federal Election and Since
In the campaign leading up to the Oct. 19, 2015 federal election, three parties addressed 
prescription drug access:
• The Green party pledged to implement a national pharmacare plan that would save 
$11 billion per year through bulk purchasing and also to apply a “gold standard” for 
pharmaceutical review to reject drugs that “hurt more people than they heal”;67
• The New Democratic Party pledged to work with the PTs to develop public, universal 
drug coverage through bulk purchasing and price negotiations and also to streamline 
the drug review and listing process;68 and
• The Liberal party pledged to join the pCPA, to address over-prescribing and adverse 
drug effects, and to review the Patented Medicines Prices Review Board (PMPRB).69
Following the Liberal government’s election, the mandate letters of the new ministers 
were made public. Health Minister Jane Philpott’s contained the following with respect to 
prescription drugs as part of a new health accord:
“It should … improve access to necessary prescription medications. This will include 
joining with provincial and territorial governments to buy drugs in bulk, reducing the 
64 
“Principles & Priorities: Pharmacare 2.0,” Canadian Pharmacists Association discussion paper, https://www.pharmacists.ca/
cpha-ca/assets/File/cpha-on-the-issues/Pharmacare%20Principles%20and%20Priorities%20Discussion%20Paper.pdf. 
65 
“Federal Policy Action to Support the Health Care Needs of Canada’s Aging Population” (Conference Board of Canada, 
2015), https://www.cma.ca/Assets/assets-library/document/en/advocacy/conference-board-rep-sept-2015-embargo-en.pdf. 
66 A. Blomqvist and C. Busby, “Feasible Pharmacare in the Federation: A Proposal to Break the Gridlock” (C.D. Howe 
Institute, 2015), https://www.cdhowe.org/sites/default/files/attachments/research_papers/mixed/e-brief_217_0.pdf..
67 “Building a Canada that works. Together,” Green Party of Canada campaign platform 2015, https://www.greenparty.ca/sites/
default/files/platform_english_web.pdf.
68 
New Democratic Party of Canada. “Building the country of our dreams: Tom Mulcair’s plan to bring change to Ottawa,” 
New Democratic Party of Canada campaign platform 2015, http://xfer.ndp.ca/2015/2015-Full-Platform-EN.pdf. 
69 
“Investing in health and home care,” Liberal Party of Canada campaign pamphlet 2015, https://www.liberal.ca/files/2015/10/
Investing-in-health-and-home-care.pdf.
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cost Canadian governments pay for these drugs, making them more affordable for 
Canadians, and exploring the need for a national formulary.”70
The federal government drug programs are now participating in the pCPA. In speeches 
since the election, Philpott has indicated that she hopes to explore how to extend the 
pCPA to private insurance plans and that she is pursuing a common drug formulary for 
publicly funded drug plans.71 The PMPRB issued a discussion paper on the modernization 
of its guidelines in June 2016 to launch a review.72 In a January 2017 interview, Philpott 
commented on the seven comparator countries against which PMPRB sets prices. She noted 
that the group includes two countries with the highest prices, the U.S. and Germany, and 
suggested that countries with lower prices, such as Australia and New Zealand, be included 
instead. When pressed on the issue of a national pharmacare program, she emphasized that 
Canada has the second highest per-capita prescription drug prices and said that it would be 
irresponsible to lock in to them.73
The pCPA has had some success. It reported that, as of April 2016, joint negotiations on 
brand name drugs and price reductions on generic drugs have resulted in estimate annual 
savings of $712 million. As of Dec. 31, 2016, it was reported that negotiations had been 
completed for 129 brand name drugs and that 43 more were underway.74
There seems little doubt that the sustained efforts by Gagnon, Morgan and colleagues 
were influential in the decision by the House of Commons standing committee on health 
(HESA) to adopt “a study on the development of a national Pharmacare program as an 
insured service for Canadians” on March 7, 2016.75 Morgan, Gagnon and Dr. Danielle 
Martin were in fact among the first to appear before HESA, after government agencies such 
as the Canadian Agency for Drugs and Technologies in Health, PMPRB and CIHI. Martin 
articulated five recommendations for a plan:76
• A public plan that covers every Canadian;
• An “evidence-based” and “transparent” process that operates at “arm’s length” from 
government and industry to decide which drugs are covered;
• Zero or very low co-payments;
• Bulk purchasing by the government in order to lower drug prices;
• A plan that encourages optimal prescribing and improves drug “quality and safety.”
70 
Canada. Office of the Prime Minister, minister of health mandate letter, http://pm.gc.ca/eng/minister-health-mandate-letter. 
71 Remarks from the Hon. Jane Philpott, minister of health, to the Canada 2020 health summit, September 29, 2016,  
http://news.gc.ca/web/article-en.do?nid=1134769. 
72 “PMPRB guidelines modernization discussion paper” (Patented Medicine Prices Review Board, 2016),  
http://www.pmprb-cepmb.gc.ca/CMFiles/Consultations/DiscussionPaper/PMPRB_DiscussionPaper_June2016_E.pdf. 
73 Interview with Minister of Health Jane Philpott, The Fifth Estate, January 13, 2017, http://www.cbc.ca/fifth/blog/full-
interview-with-minister-of-health-jane-philpott. 
74 Council of the Federation website, “The Pan-Canadian Pharmaceutical Alliance,” http://www.pmprovincesterritoires.ca/en/
initiatives/358-pan-canadian-pharmaceutical-alliance, accessed 02/03/17.
75 House of Commons Standing Committee on Health, minutes of proceedings, March 7, 2016, http://www.parl.gc.ca/
HousePublications/Publication.aspx?Language=e&Mode=1&Parl=42&Ses=1&DocId=814258. 
76 House of Commons Standing Committee on Health, evidence, April 18, 2016, http://www.parl.gc.ca/content/hoc/
Committee/421/HESA/Evidence/EV8197723/HESAEV07-E.PDF.
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From April 2016 to Feb. 2, 2017, HESA heard from numerous other witnesses (82 in total) 
and received 26 briefs from various stakeholders. A profile of the participants is found 
in Appendix B. Taken together, the briefs and testimonies addressed many questions at 
the heart of the pharmacare debate. It is notable that, as of Feb. 2, 2017, there has been no 
representation to HESA from the pCPA or provincial drug plans. In addition, the closest thing 
there has been to a representation from employers was one from the Surrey Board of Trade.
There has been widespread agreement among witnesses that Canada’s current patchwork 
of drug plans has resulted in an important coverage gap. Most participants highlighted 
that Canada is the only OECD country with a public health-care system that excludes 
pharmaceutical coverage. Many also mentioned that 10 per cent of Canadians report not 
adhering to a prescription because of its cost. Most participants — including government 
agencies, patient and health professional groups — agreed that a national pharmaceutical 
program of some sort should be implemented in Canada. Labour and trade organizations 
advocated for a national program to replace employer-sponsored drug plans, as many 
employers who cannot sustain rising drug prices have begun shifting costs to workers.77, 78  
Relieving the burden of financing prescriptions, they argued, would allow employers to 
provide other health benefits. 
A few stakeholders, however, did not support a national public program. For instance, Dr. 
Ake Blomqvist, appearing on behalf of the C.D. Howe Institute, stated that “we do not 
think that an attempt to create a universal single-payer public plan would be helpful at 
this stage.”79 Speaking on behalf of the Canadian Life and Health Insurance Association 
(CLHIA), its president, Frank Swedlove, suggested that “the best solution for Canadians 
will be the one that leverages the strengths of both the public and private sectors and brings 
them together in a co-ordinated way.”80 
The creation of an evidence-based national drug formulary, developed and maintained by 
an expert panel at arm’s length from government and industry, was very widely supported. 
It was argued that such a formulary, along with an online database containing information 
about the drug-approval process, best practice for pharmaceuticals, and post-market 
research, would promote coverage consistency across Canada, improve cost-efficiency 
through generic and bulk purchasing and increase drug safety and optimal prescribing. 
Some patients and researchers, however, identified challenges: The formulary would have 
to be kept current; provide enough variety to meet the unique needs of patients; be designed 
with attention to how individuals of different sexes, genders, races, ethnicities and socio-
economic and indigenous statuses access and use drugs; and would include drugs for rare 
diseases, all without compromising research and development. 
77 Submission from the Canadian Labour Congress to the Standing Committee on Health regarding the development of a 
national pharmacare program (2016), http://www.parl.gc.ca/Content/HOC/Committee/421/HESA/Brief/BR8604329/br-
external/CanadianLabourCongress-e.pdf. 
78 
“Development of a National Pharmacare Plan” (Canadian Union of Public Employees, 2016), http://www.parl.gc.ca/Content/
HOC/Committee/421/HESA/Brief/BR8449063/br-external/CanadianUnionOfPublicEmployees-e.pdf.
79 House of Commons Standing Committee on Health, evidence, September 27, 2016, http://www.parl.gc.ca/content/hoc/
Committee/421/HESA/Evidence/EV8442679/HESAEV20-E.PDF.
80 House of Commons Standing Committee on Health, evidence, May 9, 2016, http://www.parl.gc.ca/content/hoc/
Committee/421/HESA/Evidence/EV8251913/HESAEV10-E.PDF.
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First-dollar coverage was often recommended; witnesses cited evidence that even small 
co-payments are barriers to coverage.81 There was also significant support across briefs 
for a pharmacare program that is similar to or integrated into medicare. For instance, the 
Health Charities Coalition of Canada recommended that provinces and territories “receive 
increased transfer payments to implement comprehensive, evidence-based, pan-Canadian 
pharmacare standards.”82 
On Sept. 27, 2016, HESA decided to request that the Parliamentary Budget Office (PBO) 
estimate the cost of implementing national pharmacare.83 The parameters of the proposed 
study are outlined in Appendix C. On Dec. 13, 2016, the PBO informed HESA that the study 
would “require two full-time analysts over an expected six-month period and that the total cost 
of data from various sources will exceed $100,000.”84 The terms of reference proposed for the 
study are not yet public, but the HESA minutes of Dec. 13th indicate that the PBO was asked 
to proceed with the study with the addition of the impact of exemptions from co-payments 
indicated in the British National Health Service (e.g., pregnant women).85 On Dec. 22, 2016, 
the PBO wrote to the deputy minister of Health Canada to inquire if the department was 
already in possession of some of the data needed for its study, and the department replied on 
Jan. 13, 2017, indicating that the information requested was enclosed.86, 87
In December 2016, HESA heard from the chair of the Citizens’ Reference Panel on 
Pharmacare in Canada. Convened with a research grant from the Canadian Institutes of 
Health Research and other partners, Steve Morgan and colleagues assembled a group 
of 35 randomly selected citizens from across Canada to come together to hear from 
many stakeholders and experts, and develop a set of suggestions for pharmacare. Having 
established a basis of principles that pharmacare should be “universal, evidence-based, 
patient-centered, sustainable and accountable,” the panel recommended: 
• A pharmacare program that covers all Canadians;
• An evidence-based, patient-centered national formulary that increases drug safety 
while providing enough variety to meet unique patient needs and rare diseases;
• A publicly funded plan with drugs purchased in bulk to decrease prices;
• Private insurance that can be purchased, but covers only drugs outside the national 
formulary;
81 M. Robertson, “Understanding the Gaps in Drug Coverage in Canada’s Health Care System,” policy brief (2016),  
http://www.parl.gc.ca/Content/HOC/Committee/421/HESA/Brief/BR8614898/br-external/RobertsonMaryLou-e.pdf.
82 
“Brief to the House of Commons Standing Committee on Health: Development of a National Pharmacare Program” (Health 
Charities Coalition of Canada, 2016), http://www.parl.gc.ca/Content/HOC/Committee/421/HESA/Brief/BR8290876/br-
external/HealthCharitiesCoalitionOfCanada-e.pdf. 
83 House of Commons Standing Committee on Health, minutes of proceedings, September 27, 2016, http://www.parl.gc.ca/
HousePublications/Publication.aspx?Language=e&Mode=1&Parl=42&Ses=1&DocId=8444783. 
84 House of Commons Standing Committee on Health, evidence, December 13, 2016, http://www.parl.gc.ca/
HousePublications/Publication.aspx?Language=e&Mode=1&Parl=42&Ses=1&DocId=8701248. 
85 House of Commons Standing Committee on Health, minutes of proceedings, December 13, 2016, http://www.parl.gc.ca/
HousePublications/Publication.aspx?Language=e&Mode=1&Parl=42&Ses=1&DocId=8708149.
86 
Letter to Mr. Simon Kennedy (Office of the Parliamentary Budget Office, December 22, 2016), http://www.pbo-dpb.gc.ca/
web/default/files/Documents/Info%20Requests/2016/IR0273_HC_Estimates_National_Pharmacare_Program_EN.pdf. 
87 
S. Kennedy, Letter to Jean-Denis Fréchette (January 13, 2017), http://www.pbo-dpb.gc.ca/web/default/files/Documents/
Info%20Requests/2017/IR0273_2017_01_13_Estimates_National_Pharmacare_EN.pdf. 
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• Equal access to medications across the country;
• Immediate action by the government to fund a minimal list of drugs; and
• Development of a strategy to address orphan drugs for rare diseases.88
The briefs and testimony provided to HESA to date have outlined numerous perspectives 
on how a national pharmacare program should be designed and they advocate for the 
implementation of such a program. Many organizations and patient groups also provided 
recommendations specific to the communities they serve. It seems likely that the 
pharmacare study will not be completed until after the committee receives the PBO report 
later this year.
CONSIDERATIONS IN MOVING FORWARD
The recent concerted attention raises the question: Has the time finally come in Canada for 
a single-public-payer national pharmacare program? The foregoing would suggest that there 
are four main issues or questions that need to be addressed/resolved:
• What would be the incremental cost to the public purse of adopting a single-payer 
national pharmacare program?
• What are the prospects of federal-provincial/territorial collaboration in moving toward 
such a program?
• Who would be the winners and losers if such a program were implemented? 
• What is the state of public and employer opinion toward national pharmacare?
Incremental cost: The most recent proposals provide a range of estimates depending on 
whether the program implemented is a full public program or a catastrophic program 
designed to close the gap for uninsured or underinsured people. 
Gagnon’s 2014 estimate (with revised industrial policies) based on 2012–13 figures is that 
total prescription drug costs in a pharmacare program would be $18.8 billion. This is about 
$6.8-billion greater than the 2012 level of $12.0 billion in public funding89 (fiscal year data 
not available). Gagnon notes that there would be additional savings of $2.5 billion from the 
elimination of administrative costs in private plans and the elimination of tax subsidies.52, 90  
Morgan et al.’s base scenario estimates that for 2012–13 there would be an increase in 
public funding of $958 million, and that this would range from an increase of $5.4 billion 
if all model parameters were set to the worst-case values, to a decrease in public funding 
of $2.9 billion if they were set to best-case values.91 A 2016 study carried out by PDCI 
Market Access Inc. for the Canadian Pharmacists Association that did not model estimates 
of potential savings, estimated that on a base of $11.3 billion of 2015 public expenditures, 
a public program with no co-payment would increase public spending by $16 billion.92 
88 
“Necessary Medicines: Recommendations of the Citizens’ Reference Panel on Pharmacare in Canada” (Citizens’ Reference 
Panel on Pharmacare in Canada, 2016), http://www.crppc-gccamp.ca/s/CRPPC-Final-Report.pdf.
89 CIHI, “Prescribed drug.”
90 Pharmaceutical Management Agency, “Introduction.”
91 ibid.
92 
“Pharmacare Costing in Canada: Estimated Costs of Proposed National Pharmacare Programs” (PDCI Market Access Inc., 
2016), http://www.pdci.ca/publications/PDCI-Pharmacare-Costing-Study-Report-Feb-28-2016-Final.pdf.
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PDCI also provided estimates of a public-private model along the lines of the Quebec drug 
program. This would result in increased public spending of $2.1 billion, which is in the 
range of the Conference Board estimate of $1.6 billion for a federally funded catastrophic 
program using a three-per-cent household-income threshold.93
Most recently, Morgan et al. modelled the cost of introducing universal public coverage of 
117 essential medicines that accounted for 44 per cent of all prescriptions and 36 per cent 
of total prescription drug expenditures in 2015 in Canada. They developed three scenarios 
based on variations in changes in utilization and the prices of brand name and generic 
essential medicines. In their base case, they estimated that public spending would increase 
by $1.2 billion on a 2015 base of $10.8 billion, and private spending would decrease by $4.3 
billion on a 2015 base of $15.4 billion; there would be a total reduction of $3.0 billion in 
prescription drug spending on a base of $26.2 in total spending.94
The study that the PBO has been asked to do (Appendix C) is very comprehensive and will 
surely inform the discussion and debate further.
Prospect of FPT Collaboration on Pharmacare
At the present time, fiscal prospects suggest that the likelihood of either a full federal 
pharmacare program, or one in partnership with the provinces/territories, appears slim. 
The only funding pledge for health in the 2015 Liberal election platform was for $3 billion 
for home care over four years.95 At their January 2016 meeting, the federal, provincial and 
territorial health ministers did agree that improving the affordability and accessibility of 
prescription drugs is a shared priority and Philpott agreed to join a federal-provincial-
territorial working group.96 
A main concern of the PT governments has been the impending reduction in the Canada 
Health Transfer (CHT) to three per cent in 2017–18. At their summer 2016 meeting, the 
premiers called for a meeting with the prime minister to develop a long-term agreement on 
health-care funding, and they also stressed that any new accord would have to respect the 
principle of asymmetrical federalism.97 PT finance and health ministers repeated the call 
prior to their meeting with Philpott on Oct. 17, 2016.98 
The ministers of finance and health from the two levels of government met again on Dec. 
19, 2016. The PT ministers pushed for a 5.2-per-cent CHT escalator,99 and the federal 
93 ibid.
94 S. Morgan et al., “Estimated effects of adding universal public coverage of an essential medicines list to existing public 
drug plans in Canada,” Canadian Medical Association Journal 189 (February 27, 2017): E295-302.
95 Liberal Party of Canada, “Investing.”
96 Conference of Federal-Provincial-Territorial Ministers of Health, news release, January 21, 2016, http://www.scics.ca/en/
product-produit/news-release-statement-of-the-federal-provincial-territorial-ministers-of-health/. 
97 Council of the Federation, “Health care sustainability,” news release, July 22, 2016, http://www.canadaspremiers.ca/
phocadownload/newsroom_2016/health_care_sustainability_ july22.pdf. 
98 Conference of Provincial-Territorial Ministers of Health, “Finance and health ministers seek funding partnership with the 
federal government,” news release, October 17, 2016, http://www.scics.ca/en/product-produit/news-release-finance-and-
health-ministers-seek-funding-partnership-with-the-federal-government/. 
99 Bruce Campion-Smith, “Health talks fail despite federal pledges of more cash for home care, mental health,” Toronto Star, 
December 19, 2016, https://www.thestar.com/news/canada/2016/12/19/provinces-reject-ottawas-pitch-on-healthcare.html.
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government offered 3.0 per cent plus $11.5 billion over 10 years for home care, mental 
health and initiatives on prescription drugs and health innovation.100 The meeting concluded 
with no deal, but on Dec. 22 it was announced that an agreement had been reached with 
New Brunswick, whereby the province would get its share (per capita) of the $11.5 billion101 
and, since then, all other jurisdictions have signed deals with the federal government, 
with the exception of Manitoba.102 While the PBO 2016 Fiscal Sustainability Report made 
the case that federal fiscal prospects remain brighter than those of the PTs (reporting the 
federal fiscal gap at -0.9 per cent of GDP, versus a PT gap of 1.5 per cent of GDP),103 the 
Department of Finance issued a report in December projecting that the federal government 
could run deficits until 2055–56.104 Hence, the prospect of a federal contribution to a 
pharmacare program, even a partnership model, seems highly unlikely for the foreseeable 
future, at least for the duration of the government’s current mandate.
Winners and Losers 
In her testimony to HESA Dr. Danielle Martin noted “We have to understand that there’s a 
lot of money in the drug industry in Canada and that there are always going to be winners 
and losers in every transition. We need to look to you as political leaders to show leadership 
in the politics of the transition.”105 It is important to understand who the winners and 
losers are, both from the perspective of likely support — and likely opposition — to policy 
proposals, but also from the standpoint of the side effects that a pharmacare program might 
create. The most obvious losers in the proposals for single-payer public pharmacare are the 
brand name and generic pharmaceutical industries as a result of price reductions and the 
private insurance industry, and the most obvious winner is ultimately expected to be the 
patient/taxpayer. One question that has not been examined to any degree over the course of 
the various pharmacare proposals is how viable the supplementary-health-benefits industry 
would be if a public pharmacare program were to be put in place.
According to CLHIA, the $32.2 billion paid out in supplementary health-insurance benefits 
in 2015 was distributed as follows:
• Prescription drugs – 33 per cent
• Dental care – 24 per cent
• Paramedic and vision – nine per cent
• Hospital accommodation – six per cent
• Travel insurance - three per cent
100 
Department of Finance, “Federal Proposal to Strengthen Health Care for Canadians,” http://www.fin.gc.ca/n16/data/16-
161_1-eng.asp. 
101 
Government of Canada, “Canada-New Brunswick reach agreement on funding for health accord,” news release,  
December 22, 2016, http://news.gc.ca/web/article-en.do?nid=1173099. 
102 Health Canada, “Canada reaches health funding agreement with Ontario,” news release, March 10, 2017,  
https://www.canada.ca/en/health-canada/news/2017/03/canada_reaches_healthfundingagreementwithontario.html. 
103 
Office of the Parliamentary Budget Officer, “Fiscal Sustainability Report 2016” (June 28, 2016), http://www.pbo-dpb.gc.ca/
web/default/files/Documents/Reports/2016/FSR_2016/FSR_2016_EN.pdf. 
104 
Department of Finance, “Update of long-term economic and fiscal projections 2016,” https://www.fin.gc.ca/pub/ltefp-peblt/
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• Disability – 21 per cent
• Other – four per cent106
With prescription drugs comprising one-third of the business, this question warrants 
attention. In responding to a question at the HESA hearings about the impact of a public 
pharmacare program on the private health insurance industry, CLHIA’s president, Frank 
Swedlove, answered: “there are a number of companies that operate exclusively in the 
supplementary health business. Of course they can continue to offer the non-drug portion, 
but their business would be affected.”107 He continued on to single out Blue Cross and other 
not-for-profit firms. 
This was reinforced by the testimony of Diane Balon of Alberta Blue Cross to HESA on 
Feb. 2, 2017. Noting that the HESA study focuses on pharmacare, she said “any changes to 
the funding model for drug coverage should consider the potential implications that it could 
have to the coverage level for other benefits. These benefits include things like diabetic 
supplies, psychology services, physiotherapy benefits, wellness initiatives, and a host of 
other medical services that address individuals’ health needs holistically.”108 
Clearly this would require further study, but at one-third of the supplementary-health-
benefits business, prescription drug insurance supports a large infrastructure that serves 
as a backbone for all supplementary benefits. Removal of prescription drugs would require 
a rescaling of the health insurance business. It would be of particular concern if there 
were any implications for dental insurance coverage, which represented one-fourth of 
the business in 2015. Analysis of Statistics Canada’s 1996/97 National Population Health 
Survey showed that 73 per cent of individuals with dental insurance had visited a dentist in 
the past year, compared with 45 per cent of those without dental insurance.109 Attention to 
the importance of oral health is growing,110 and yet access to dental care is simply not on 
the policy agenda. As shown in Table 1, with six-per-cent public funding of dental-office 
visits in 2012, Canada was almost six times below the OECD average for 22 countries.
Another aspect of winners and losers has been the recent furor over a story appearing in 
the National Post on Dec. 3, 2016 citing unnamed sources who indicated that the federal 
government is considering taxing private health and dental plans. Their tax exemption is 
projected to result in a tax expenditure costing the government $2.9 billion in 2017.111, 112  
This tax reform was most recently proposed by the Advisory Panel on Healthcare 
106 Canadian Life and Health Insurance Facts (Canadian Life and Health Insurance Association, 2016), https://www.clhia.ca/
domino/html/clhia/CLHIA_LP4W_LND_Webstation.nsf/resources/Factbook_2/$file/2016+CLHIA+Factbook+ENG.pdf. 
107 Standing Committee on Health, evidence, May 9, 2016.
108 House of Commons Standing Committee on Health, evidence, February 2, 2017, http://www.parl.gc.ca/content/hoc/
Committee/421/HESA/Evidence/EV8729943/HESAEV39-E.PDF.
109 W. Millar and D. Locker, “Dental insurance and use of dental services,” Health Reports 11, 1 (1999): 55-67.
110 A. Weil, “Oral health,” Health Affairs 35, 12 (2016): 2163.
111 John Ivison, “Liberals eye tax on private health and dental plans, a move that would take in about $2.9 B,” National Post, 
December 3, 2016, http://news.nationalpost.com/news/canada/canadian-politics/federal-liberals-eye-tax-on-private-health-
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Department of Finance, “Report on federal tax expenditures 2016,” https://www.fin.gc.ca/taxexp-depfisc/2016/taxexp-
depfisc16-eng.pdf.
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Innovation,113 and Gagnon had included the elimination of the tax subsidy as an offsetting 
measure in his 2010 proposal. This resulted in an immediate reaction from stakeholders, 
primarily based on a study of the Quebec decision to treat the employer contribution to 
health and dental benefits as taxable income beginning in 1993. The study found that 
this measure resulted in a 13 -to 14-percentage-point drop in workplace coverage in the 
province.114 A coalition of eight health-professional associations who would be impacted by 
any measure that would reduce employer-provided health insurance launched a campaign 
called “Don’t Tax My Health Benefits,” which invited the public to write to their member 
of Parliament (MP). The website indicates that more than 80,000 Canadians have done 
so.115 Similarly, the Canadian Chamber of Commerce created a template email for its 
members to send to the federal finance minister and their MP.116 The Canadian Federation 
of Independent Business has provided a bulletin to its members outlining the implications 
of the potential tax measure and encouraging them to visit the coalition’s website.117
The coalition subsequently commissioned research from the Conference Board of Canada 
that was pre-released in the National Post on Jan. 29. It suggested that middle-income 
earners (in receipt of employer-sponsored health benefits) will pay an additional $1,000 in 
federal and provincial income tax should the taxation of health and benefits go through.118, 
119 This led to a question in the House of Commons on Feb. 1 by interim Conservative 
Leader Rona Ambrose as to why the government would even consider such a tax. In his 
reply, Prime Minister Justin Trudeau answered “we are committed to protecting the middle 
class from increased taxes and that is why we will not be raising the taxes the member 
opposite proposes we will do”.120 
On Feb. 2 the Conservative party introduced the following motion: “That, given the 
average middle class Canadian is already overburdened with taxes, the House call on the 
government to abandon any plans it may have to in any way tax health and dental care 
plans.”121 During the debate over the issue, the parliamentary secretary to the government 
leader in the House of Commons stated that “the Prime Minister and his government have 
113 “Advisory Panel on Healthcare Innovation. Unleashing Innovation: Excellent Healthcare for Canada” (Advisory Panel 
on Healthcare Innovation, 2015), http://www.healthycanadians.gc.ca/publications/health-system-systeme-sante/report-
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been very clear. There is not going to be a tax on health and dental plans.”122 The motion 
was subsequently defeated on Feb. 7 by a vote of 175 to 138.123 There was no mention of 
such a measure in the 2017 Budget, hence it is off the table for the time being.
State of Public and Employer Opinion
Since 2012, at least eight national public opinion surveys and three employer surveys have 
been conducted that have asked questions pertinent to pharmacare. The findings suggest 
several key observations.
• Pharmacare is not a “top-of-mind” issue for most Canadians. A 2012 survey by Ekos 
Research Associates found that, when asked an open-ended question about the most 
important issue facing Canadians today, cost of health care/medication ranked fourth 
at seven per cent, well behind the top three, which all related to access and wait times 
and accounted for 40 per cent of the respondents. When asked about how serious a 
problem they thought each of 10 issues is with respect to Canadians’ health and the 
health-care system, lack of access to prescription medication ranked 10th, with 47 per 
cent rating it as a serious problem compared with the top-ranked 83-per-cent rating 
for the increasing demands on the system resulting from an aging population.124 
Similar results were obtained in 2016 surveys by Pollara125 and Ipsos.126
• Nonetheless, when asked about pharmacare, Canadians agree that it is a good idea. 
A 2015 survey by the Angus Reid Institute found that almost nine in 10 (88 per 
cent) agreed that “every Canadian — regardless of income — should have access to 
necessary prescription medicine” and there was a similar level of support for adding 
prescription drugs to medicare.13 Similar support is found in surveys by Abacus Data 
(2015)127 and Ekos Research Associates (2016).128
• Canadians value employer-provided supplementary health benefits. A 2012 survey by 
Ipsos found that among those with such benefits, four in 10 (42 per cent) indicated that 
benefits would be a factor in deciding whether to switch jobs,129 and a 2016 survey by 
Ipsos found that 70 per cent of respondents were opposed to the taxation of health and 
dental benefits.130
122 House of Commons, debates, February 1, 2017.
123 Canada. House of Commons, debates, February 7, 2017, http://www.parl.gc.ca/content/hoc/House/421/Debates/135/
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• Surveys indicate contradictory support for how pharmacare should be implemented. 
The 2015 Abacus Data survey found that, when presented with three options for 
a pharmacare program, almost one in two respondents (46 per cent) supported a 
program that would cover Canadians who are not currently covered by a government 
or private plan; almost one in three (31 per cent) supported a single program that 
would replace all existing government and private plans; and just over one in five 
(21 per cent) supported a program that would only cover Canadians facing extreme 
circumstances such as expensive drugs for rare diseases.131 In contrast, the 2016 
Pollara survey found that, when asked to select the best approach for ensuring that 
all Canadians have access to prescription medications from among three options, 
39 per cent chose a single national public pharmacare plan operated by the federal 
government and funded by taxes collected by the federal government; 19 per cent 
chose separate regional pharmacare plans in each province and territory, funded by 
taxes collected by both the federal government and the provincial governments; 17 
per cent chose private prescription plans operated by private insurance companies, 
supplemented by a public prescription drug plan provided by the federal government 
for persons with high out-of-pocket drug costs; and 25 per cent chose “don’t know.”132
• Employers value the provision of supplementary benefits as a competitive edge 
for attracting employees. A 2012 employer survey by Ipsos Reid found that more 
than eight out of 10 (85 per cent) employers indicated that even if the government 
introduced a pharmacare program, they would still recommend that their business offer 
supplementary benefits as it would provide an advantage in recruiting and retaining 
employees.133 Aon Hewitt reported a similar finding on a 2015 employer survey.134 
• Like the population surveys, the two 2015 employer surveys show contradictory 
evidence about the level of support for how pharmacare should be implemented. The 
Aon Hewitt survey found that almost nine in 10 (88 per cent) agreed that a government-
run program with principles similar to the Canada Health Act would be a positive 
solution,135 while a Benefits Canada survey found that almost nine in 10 (87 per cent) 
supported “a publicly funded national catastrophic drug program to take some of the 
cost pressures off plan sponsors,” while just over one in two (53 per cent) indicated 
support for a “government funded, national pharmacare program for all Canadians to 
replace current provincial and private drug benefit programs such as yours.”136
In summary, while the survey results show strong support among the public and employers  
for all Canadians having access to prescription drugs, the evidence is much less clear on  
how it should be implemented and how it should be funded. Should governments want  
to take this issue on, they would be well advised to consider a deliberative consultation 
131 
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process much like the federal government did in the 1990s on the future of the Canada 
Pension Plan, which resulted in increases to contribution rates.137
One Other Issue: First-Dollar Coverage?
As the HESA study progresses, one issue that bears examination is the feasibility/
affordability of first-dollar coverage for prescription drugs. It would seem that it has been 
implicitly assumed that some level of co-payment would be required for prescription drugs; 
as noted previously, the Hall report recommended a $1.00 charge in 1964. In England, 
which does include drugs in the National Health Service (NHS), the current prescription 
charge is 8.40 pounds, although 90 per cent of prescription items are provided free of 
charge.138, 139 Appleby has noted, however, that in Wales, Northern Ireland and Scotland, the 
NHS has eliminated prescription charges.140 One observational study of dispensing rates in 
Wales found that the overall impact of removing prescription charges was minimal.141 Table 
3 is only a superficial look at the volume of prescriptions dispensed in Scotland from 2009–
15, years that straddle the removal of prescription charges on April 1, 2011, but it indicates 
that, after 2012, the growth in annual volumes dispensed began to diminish. It should be 
added, however that patient charges accounted for less than four per cent of dispensing 
expenditures in 2010.142 The experience of these jurisdictions merits closer investigation.
TABLE 3 PRESCRIPTION DISPENSING IN SCOTLAND, 2009–15
Year Number of Prescriptions  
(million)
% increase from previous year
2009 88.4 3.8
2010 91.0 3.0
2011 93.8 3.1
2012 96.6 3.0
2013 98.4 1.9
2014 100.6 2.2
2015 102.0 1.4
Source: Annual tabulations: Remuneration and reimbursement details for all prescribing made in Scotland. 
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Conclusion
In conclusion, the answer to the question “has the time come for national pharmacare?” is 
“not yet” — at least not within the current mandate of the federal government. Whatever 
ultimate savings might be obtained from bulk purchasing and generic prescribing, in the 
short to medium term there will be transition costs to government that greatly exceed the 
$11.5 billion that the federal government has put forward for the next 10 years (on top of 
the 3% increase in the CHT). Even the incremental proposals most recently costed by the 
Conference Board and Morgan et al. exceed this amount (assuming an annual average 
of $1.15 billion). Moreover, the emergence of bilateral agreements and the emphasis on 
asymmetrical federalism would seem to run counter to the establishment of new national 
standards in the health-care arena. Considering the proposals put forward, the plan put 
forward by Kirby in 2002 still seems to be the most workable approach for a cost-shared 
scalable scheme between the federal and provincial/territorial governments and private 
drug plans that would constitute a step toward a national plan. The prodigious efforts 
of those who have opened a policy window that has led to the HESA study are to be 
commended, and hopefully that report will lead to serious deliberation about universal 
access to prescription drugs, possibly in the campaign leading up the federal election slated 
for October 2019. Finally, we must bear in mind that in order to sustain any drug program, 
it will be essential to address a broader array of elements of a pharmaceutical strategy, as 
originally set out in the Hall report and, more recently, in the 2004 health accord.
March 23, 2017 
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APPENDIX A
PROPOSALS/MODELS AND ESTIMATES OF PUBLIC  
FUNDING FOR PHARMACARE 1964–2017
1964 — Royal Commission on Health Services (Hall). Federal government would cover 50 
per cent of the cost of a drug benefit program. $1.00 prescription charge. It was estimated 
that this would require public funding of $163 million in 1966, from a base cost of 
essentially zero.
1971–72 — Health ministers develop a drug price program that would extend medicare to 
prescription drugs (source is archival memoranda reviewed by Boothe).
1997 — National Forum on Health. “Expand publicly funded services to include all 
medically necessary services, and, in the first instance, home care and drugs.” As 1994 was 
cited as the reference year, this would have required an increase of $3.5 billion in public 
funding on top of the existing $3.0 billion in public funding.
1997 — Palmer D’Angelo Consulting Inc. Developed seven models with variations on 
public/private and level of co-payment. Public funding in 1996 was $3.0 billion. Public no-
co-payment model would increase public funding by $4.3 billion. Public/private model with 
patient paying dispensing fee would increase public funding by $217 million.
2002 — Palmer D’Angelo Consulting Inc. Updated the seven models developed in 1997, to 
2001. Public funding in 2001 was $5.5 billion. Public no-co-payment model would increase 
public funding by $8.1 billion. Public/private model with patient paying dispensing fee 
would increase public funding by $1.2 billion.
2002 — Royal Commission on the Future of Health Care in Canada (Romanow). 
Recommended a catastrophic-drug transfer of $1.0 billion (modelled on Manitoba’s 
experience) that would reimburse 50 per cent of the costs of provincial and territorial public 
drug plans above a threshold of $1,500 per person, per year.
2002 — Standing Senate Committee on Social Affairs, Science and Technology (Kirby). 
Recommended that the federal government pay 90 per cent of costs above $5,000 for 
individuals covered by provincial-territorial drug plans, with family drug expenditures 
capped at three per cent of total family income. A similar provision would apply to private 
insurance plans with the stipulation that individual plan member’s costs would be capped 
at the lesser amount of three per cent of family income or $1,500. Estimated to cost $500 
million per year.
2006 — National Pharmaceuticals Strategy (NPS) Progress Report. Developed four models 
of catastrophic coverage based on variations of a variable/fixed percentage of catastrophic 
costs and income threshold and whether the public plan would take over catastrophic 
coverage from private plans. Base public funding assumed to be $6.6 billion. Estimates 
of increased public funding ranged from $1.4 billion, for a model that would cover 
catastrophic spending for public plans only with a fixed 4.3-per-cent threshold, to $4.7 
billion for a model that would cover catastrophic spending for public and private plans with 
a variable percentage threshold scaled to income.
2008 — Provincial-territorial health ministers. Apparently building on the 2006 NPS 
report, estimated the cost of a catastrophic drug program at $5.03 billion for 2006, 
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assuming a cap of five per cent of net income and proposed 50/50 cost sharing with the 
federal government.
2010 — Marc-André Gagnon. Developed four scenarios for full public funding on a base 
of $11.2 billion in public funding in 2008. Scenario 1: Based on current industry policies, 
would require $12.5 billion in additional public funding. Scenario 4: With savings from 
competitive purchasing, policies would require $4.7 billion in additional public funding.
2014 — Marc-André Gagnon. Updated scenarios 1 and 4 based on a 2012 base of 
$11.8 billion in public funding. Scenario 1: Based on current industry costs, policies 
would require $15.8 billion in additional public funding. Scenario 4: With savings from 
competitive purchasing, policies would require $7 billion in additional public funding.
2015 — Steve Morgan and colleagues. Developed three scenarios of public pharmacare 
with modest co-payments on a 2012–13 base of $12.2 billion in public funding, by varying 
parameters of brand-name and generic prices, changes in product selection within drug 
classes, and changes in utilization. In the base scenario, public funding would increase by 
$958 million; the worst-case scenario would increase public funding by $5.3 billion; and the 
best-case scenario would decrease public funding by $2.9 billion.
2015 — Conference Board of Canada. Modelled the cost of a public catastrophic-drug 
program that would cover all public- and private-plan expenditures above a threshold of 
$1,500 or three per cent of gross household income. This was estimated to cost $1.6 billion 
in 2016, rising to $1.8 billion by 2020.
 2016 — PDCI Market Access Inc. Updated the four public-only models from 1997 and 
2002 on a 2015 public-expenditure base of $11.3 billion and developed three models of 
pharmacare for the uninsured assuming continued existing public-private coverage. Public 
no-co-payment model would increase public funding by $16.0 billion. Among the three 
models of pharmacare for the uninsured, a modified Quebec program would increase public 
funding by $2.2 billion, a P.E.I. generic-drug-plan model would increase public funding by 
$93 million, and a private model would increase private insurance funding by $2.3 billion.
2017 — Morgan et al. Developed three scenarios for the introduction of universal public 
coverage of 117 essential medicines on a 2015 public-expenditure base of $10.8 billion. 
Depending on assumptions of changes in utilization and prices of brand-name and 
generic essential medicines, public expenditure would increase by $1.2 billion and private 
expenditure would decrease by $4.3 billion. The worst-case scenario would increase public 
funding by $1.9 billion and the best case would increase it by $373 million.
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APPENDIX B 
PROFILE OF WITNESSES AND BRIEFS PRESENTED TO THE STANDING  
COMMITTEE ON HEALTH (HESA) IN ITS STUDY OF NATIONAL PHARMACARE:  
APR. 13, 2016 TO FEB 2, 2017
  Government Appearing as  Individuals
Health Professionals/ 
Organizations 
Health Charities  
and Patient Groups Industry Other
Presented as a 
witness before the 
committee
Patented Medicines 
Prices Review Board 
(PMPRB)
Steve Morgan (UBC) Canadian Pharmacists Association 
Canadian Association  
of Retired Persons
Canadian Life and 
Health Insurance  
Association (CLHIA)
C.D. Howe Institute
Canadian Agency for 
Drugs and Technology 
in Health (CADTH)
Christopher McCabe (U 
of Alberta)
Canadian Federation  
of Medical Students Arthritis Society
Consumer Health  
Products Canada 3Sixty Public Affairs
Canadian Institute for 
Health Information 
(CIHI)
Robyn Tamblyn (McGill)
Women’s College  
Hospital  
(Danielle Martin)
Heart and Stroke  
Foundation of Canada
Innovative  
Medicines Canada Surrey Board of Trade
Office of the  
Parliamentary  
Budget Officer
Gregory Marchildon  
(U of Toronto)
UBC Therapeutics 
Initiative
Citizens’ Reference 
Panel on Pharmacare
Canadian Generic  
Pharmaceutical  
Association
Roy Romanow
Health Canada Strategic 
Policy Branch
Colleen Flood  
(U of Ottawa)     BIOTECanada  
Health Canada   
First Nations and Inuit 
Health Branch
Mélanie Bourassa 
Forcier (U Sherbrooke – 
CIRANO) 
    PCDI Market Access
Dapartment of  
National Defence
Doug Coyle  
(U of Ottawa)     Alberta Blue Cross
Office of the Auditor 
General of Canada Larry Lynd (UBC)      
Department of  
Veteran Affairs
Anne Holbrook  
(McMaster)      
  David Henry  (U of Toronto)      
  Marie-Claude  Prémont (ENAP)      
Submitted a Brief 
 
Canadian Institutes of 
Health Research David West
Independent Patient 
Voices Network  
of Canada
Cannabis Canada  
Associaiton
Canadian Labour 
Congress
   Mary Lou Robertson Canadian Cancer  Survivor Network  
Canadian Institute  
of Actuaries
    Registered Nurses  Association of Ontario
Mood Disorders  
Society of Canada    
      Union des  consommateurs    
Both (testified and 
submitted a brief)
Health Quality Ontario Marc André Gagnon (Carleton)
Canadian Nurses  
Association
Canadian Organization 
for Rare Disorders   Angus Reid Institute
Canadian Blood 
Services 
Matthew Herder  
(Dalhousie)
Canadian Medical 
Association
Canadian Diabetes 
Association  
Canadian Union of 
Public Employees
  Katherine Boothe (McMaster)
Canadian Doctors  
for Medicare
Health Charities  
Coalition of Canada  
Canadian Health 
Coalition
    Canadian Federation  of Nurses Unions      
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APPENDIX C
STANDING COMMITTEE ON HEALTH: REQUEST TO THE OFFICE OF  
THE PARLIAMENTARY BUDGET OFFICER, SEPTEMBER 29, 2016
It was agreed, — That the motion adopted Tuesday, September 27, 2016, concerning the 
Parliamentary Budget Officer be rescinded and replaced with the following: “That the 
Committee request the Parliamentary Budget Officer to provide it with an analysis of the 
following items by (specify date based on PBO’s estimate of earliest date this analysis can 
reasonably be completed):
a. The total number and percentage of Canadians:
i.  who are ineligible for full public coverage of all prescription pharmaceuticals outside 
of hospitals (under current provincial and federal programs), excluding catastrophic 
coverage, and who do not have equivalent private or employer sponsored coverage; and 
ii. whose private or employer-sponsored coverage has been reduced or eliminated in the 
past 10 years.
b. Estimate the current Canadian annual total of: 
i.  employer contributions to employer-sponsored private insurance benefit plans in respect 
of prescription pharmaceutical coverage;
ii.  employee contributions to employer-sponsored private insurance benefit plans in respect 
of prescription pharmaceutical coverage;
iii.  total out-of-pocket payments by patients for prescription pharmaceuticals;
iv.  direct and indirect government subsidies to private pharmaceutical insurance plans;
v.  expenditure on prescription pharmaceuticals broken down by province or territory and 
by source of funding;
vi.  individual expenditure on private pharmaceutical insurance coverage;
and where possible, broken down by province or territory, by urban/rural, by age quintile 
and by annual household income quintile, for all of the above information.
c.  Estimate the cost of (1) creating and (2) administering:
i.  a single-payer universal first-dollar prescription drug coverage under the Canada Health 
Act; and
ii.  a single purchaser and national distribution system for prescription drugs, possibly 
modeled on the Canadian Blood Services and/or other relevant models in Canada or 
other jurisdictions.
d.  Assume that there is a single national formulary for prescription drugs with tiers based 
on the relative importance of the health condition treated, and the relative effectiveness 
of the drug in addressing the health condition, ranging from essential medicines for tier 
1, and then proceeding to drugs that are less essential or equivalent but more costly in 
subsequent tiers.
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In terms of the financing of a single-payer prescription drug coverage program, analyze the 
efficiency of an:
i. introduction of a payroll tax;
ii. increase in sales tax;
iii. increase in corporate and/or personal income tax; and
iv. introduction of a co-pay based on France’s SMR/ASMR model.
e.  Discuss the implications of and the tools available for raising any additional revenue 
needed to finance such a program.
f. To the extent possible:
i.  estimate of the total annual savings to the health care system from eliminating cost-
related non-adherence to pharmaceutical prescriptions in Canada;
ii.  estimate of the total annual savings achievable by a single-payer, as opposed to the 
present multiplicity of public and private payers, acting as the sole original purchaser of 
prescription pharmaceuticals in Canada; and
iii.  estimate of the total annual savings from bulk buying, exclusive licensing, increased use 
of generic medicines, and evidence-based formulary.
In carrying out this analysis, the PBO will work with Canadian Institutes for Health 
Information, Statistics Canada, Canadian Agency for Drugs and Technology in Health, 
IMS Brogan and other sources to obtain appropriate data. The PBO’s report will disclose in 
detail the sources of data, the quality of the data and the methods of analysis used”.
House of Commons Standing Committee on Health. Minutes of proceedings, Meeting  
No. 21 September 29, 2016. 
http://www.parl.gc.ca/HousePublications/Publication.
aspx?Language=e&Mode=1&Parl=42&Ses=1&DocId=8462385.
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